An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.

被引：0
|
作者：
Eskens, F. A.
Planting, A.
Van Doorn, L.
Isoe, T.
Hayashi, K.
Hussain, S.
Ekman, L.
Burger, H.
Verweij, J.
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] Kirin Co Ltd, Tokyo, Japan
[3] Quintiles, Uppsala, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：87S / 87S
页数：1
相关论文
共 50 条
  • [41] A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.
    Elez, Elena
    Lenz, Heinz-Josef
    de Jonge, Maja
    Yaeger, Rona
    Doi, Toshihiko
    Pronk, Linda
    Teufel, Michael
    Marzin, Kristell
    Tabernero, Josep
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
    Ryan, Charles J.
    Stadler, Walter M.
    Roth, Bruce
    Hutcheon, Douglass
    Conry, Shauna
    Puchalski, Thomas
    Morris, Charles
    Small, Eric J.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 445 - 451
  • [43] Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
    Charles J. Ryan
    Walter M. Stadler
    Bruce Roth
    Douglass Hutcheon
    Shauna Conry
    Thomas Puchalski
    Charles Morris
    Eric J. Small
    Investigational New Drugs, 2007, 25 : 445 - 451
  • [44] A Phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Hurwitz, HI
    Eckhardt, SG
    Holden, SN
    Basser, R
    Deboer, R
    Rosenthal, M
    Rischin, D
    Swaisland, H
    Barge, A
    McKinley, M
    Wheeler, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3654S - 3654S
  • [45] A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
    Wang, Fen
    Molina, Julian
    Satele, Daniel
    Yin, Jun
    Lim, Vun-Sin
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 658 - 665
  • [46] A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors
    Fen Wang
    Julian Molina
    Daniel Satele
    Jun Yin
    Vun-Sin Lim
    Alex A. Adjei
    Investigational New Drugs, 2019, 37 : 658 - 665
  • [47] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Jazieh, Khalid
    Molina, Julian
    Allred, Jacob
    Yin, Jun
    Reid, Joel
    Goetz, Matthew
    Lim, Vun-Sin
    Kaufmann, Scott H.
    Adjei, Alex
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 307 - 314
  • [48] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
    Junning Cao
    Jian Zhang
    Wei Peng
    Zhiyu Chen
    Songhua Fan
    Weiguo Su
    Ke Li
    Jin Li
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 259 - 269
  • [49] A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
    Khalid Jazieh
    Julian Molina
    Jacob Allred
    Jun Yin
    Joel Reid
    Matthew Goetz
    Vun-Sin Lim
    Scott H. Kaufmann
    Alex Adjei
    Investigational New Drugs, 2019, 37 : 307 - 314
  • [50] Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors
    Wang, Jiayu
    Wang, Wenna
    Tong, Zhongsheng
    Shi, Yehui
    Shi, Yanxia
    Zheng, Qiufan
    Yu, Shunjiang
    Cao, Yuanyuan
    Xie, Ning
    Fan, Jianru
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345